Cyprumed's Oral Peptide Tablet Technology Enters Human Clinical Development As MSD Initiates Phase I Trial, Triggering Milestone Payment For Up To $493M From MSD

Cyprumed's oral peptide tablet technology has entered human clinical development as MSD initiates a Phase I trial for a proprietary drug candidate. This milestone triggers a payment of up to $493 million to Cyprumed under their existing collaboration agreement.